Browsing by Author TAN, JT

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 17 of 17
TitleAuthor(s)Issue Date
 
Association between glycemic control and colorectal adenoma and cancer risk in patients with type 2 diabetes mellitus: a population-based cohort study
Proceeding/Conference:Digestive Disease Week 2024 (18/05/2024-21/05/2024, , , Washington, DC, USA)
Cheung, KSMao, XTan, JTCheng, HMLeung, WKSeto, WK
18-May-2024
 
Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination
Journal:Vaccines
Cheung, KSMLam, LKKZhang, ROoi, PHTAN, JTTo, WPHui, CHChan, KHSeto, WKWHung, FNILeung, WK
2022
 
Effect of empagliflozin on liver fat in metabolic-dysfunction associated steatotic liver disease patients without diabetes mellitus: a randomized, double-blind, placebo-controlled trial
Proceeding/Conference:Digestive Disease Week 2024 (18/05/2024-21/05/2024, , , Washington, DC, USA)
Cheung, KSNg, HYHui, RWHLam, LKMak, LYHo, YCTan, JTChan, EWSeto, WK
18-May-2024
 
Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients
Journal:Vaccines
Cheung, KSLam, LKMao, XHTan, JTOoi, PHZhang, RQChan, KHHung, IFNSeto, WKYuen, MF
1-Feb-2023
 
Effects of empagliflozin on liver fat in metabolic-dysfunction associated steatotic liver disesase patients without diabetes mellitus: a randomized, double-blind, placebo controlled trial
Journal:Hepatology
Cheung, KSNg, HYHui, RWHLam, LKMak, LYHo, YCTan, JTChan, EWSeto, WKYuen, MFLeung, WK
1-Jan-2024
 
Gut microbiota predicts treatment response to empagliflozin among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus.
Proceeding/Conference:30th Medical Research Conference (30/11/2024-30/11/2024)
Ng, HYZhang, LTan, JTHui, RWHLeung, WKYuen, MFSeto, WKCheung, KS.
30-Nov-2024
 
Metabolic dysfunction-associated steatotic liver disease is a risk factor for lower vaccine immunogenicity against SARS-COV-2 omicron variant among three-dose BNT162b2 recipients
Proceeding/Conference:Medical Research Conference, the University of Hong Kong (20/01/2024-20/01/2024, , , Hong Kong)
Lam, LKTan, JTSeto, WKYuen, MFCheung, KS
20-Jan-2024
 
Modifying pancreatic cancer risk through pre-diabetes reversal: Evidence from a large population-based study
Proceeding/Conference:Asian Pacific Digestive Week (18/11/2025-22/11/2025, Singapore)
Cheung, KSTan, JTMao, XLui, DTWCheng, HMLeung, WKSeto, WK
22-Nov-2025
 
Post-endoscopic retrograde cholangiopancreatography pancreatitis independently predicts pancreatic cancer development in diabetic patients.
Proceeding/Conference:Annual Meeting, Asia Pacific Association for the Study of the Liver (26/03/2025-30/03/2025, Beijing)
Cheung, KSTan, JTMao, XSeto, WK
26-Mar-2025
 
Post-endoscopic retrograde cholangiopancreatography pancreatitis was an independent risk factor of pancreatic cancer development in patients with type 2 diabetes
Proceeding/Conference:United European Gastroenterology Week (12/10/2024-15/10/2024, Vienna)
Cheung, KSTan, JTMao, XSeto, WK
13-Oct-2024
 
Reduced risk of pancreatic cancer associated with regular aspirin use in type 2 diabetes patients.
Proceeding/Conference:United European Gastroenterology Week (12/10/2024-15/10/2024, Vienna)
Tan, JTMao, XSeto, WKCheung, KS.
12-Oct-2024
 
Sodium-glucose cotransporter-2 inhibitors associated with lower colorectal cancer risk than aspirin in diabetic metformin users.
Proceeding/Conference:Asian Pacific Digestive Week 2024 (21/11/2024-24/11/2024, Bali)
Cheung, KSMao, XTan, JTLeung, WKSeto, WK
8-Sep-2024
 
Sodium-glucose cotransporter-2 inhibitors associated with lower risk of hepatocellular carcinoma and hepatic decompensation in type 2 diabetes mellitus
Proceeding/Conference:Digestive Disease Week 2024 (18/05/2024-21/05/2024, , , Washington, DC, USA)
Cheung, KSMao, XTan, JTCheng, HMYuen, MFSeto, WK
18-May-2024
 
Sodium-glucose cotransporter-2 inhibitors were associated with lower risk of colorectal cancer and adenoma than metformin in patients with type 2 diabetes mellitus.
Proceeding/Conference:United European Gastroenterology Week (12/10/2024-15/10/2024, Vienna)
Cheung, KSMao, XTan, JTLeung, WKSeto, WK
13-Oct-2024
 
Sodium-glucose cotransporter-2 inhibitors were associated with reduced pancreatic cancer risk in metformin-treated diabetic patients
Proceeding/Conference:Asian Pacific Digestive Week (18/11/2025-22/11/2025, Singapore)
Cheung, KSTan, JTChang, LMao, XLui, DTWCheng, HMLeung, WKSeto, WK
22-Nov-2025
 
Vonoprazan-based dual and triple therapy versus bismuth-based quadruple therapy as first-line therapy for Helicobacter pylori in China: a three-arm, randomized clinical trial
Proceeding/Conference:Digestive Disease Week 2024 (18/05/2024-21/05/2024, , , Washington, DC, USA)
Cheung, KSLyu, TDeng, ZHan, SNi, LWu, JTan, JTNg, HYLeung, WKSeto, WK
18-May-2024
 
Vonoprazan-based dual and triple therapy versus bismuth-based quadruple therapy as first-line therapy for Helicobacter pylori in China: a three-arm, randomized clinical trial
Proceeding/Conference:United European Gastroenterology Week (12/10/2024-15/10/2024, Vienna)
Cheung, KSLyu, TDeng, ZHan, SNi, LWu, JTan, JTNg, HYLeung, WKSeto, WK
14-Oct-2024
Showing results 1 to 17 of 17